These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 14742928)

  • 1. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
    Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
    Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.
    Radhakrishnan VV; Sumi MG; Reuben S; Mathai A; Nair MD
    Indian J Med Res; 2003 May; 117():216-20. PubMed ID: 14609050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome.
    Radhakrishnan VV; Sumi MG; Reuben S; Mathai A; Nair MD
    Acta Neurol Scand; 2004 Jan; 109(1):71-4. PubMed ID: 14653854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    Korinthenberg R; Schessl J; Kirschner J; Mönting JS
    Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome.
    Sharief MK; McLean B; Thompson EJ
    Ann Neurol; 1993 Jun; 33(6):591-6. PubMed ID: 8498839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barré syndrome.
    Nyati KK; Prasad KN; Verma A; Paliwal VK
    J Neurosci Res; 2010 Dec; 88(16):3540-6. PubMed ID: 20936699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in Guillain-Barré syndrome.
    Tekgül H; Kütükçüler N; Cağlayan S; Tütüncüoğlu S
    Turk J Pediatr; 1998; 40(3):357-63. PubMed ID: 9763899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Guillain-Barre syndrome and IVIg: does early initiation of treatment influence the mean hospital stay?].
    Coll-Cantí J; Alvarez-Ramo R; Dorado L; Guerrero C; Serichol M; Dávalos A; Martínez EM
    Neurologia; 2009 May; 24(4):217-9. PubMed ID: 19603290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.
    Chi LJ; Wang HB; Zhang Y; Wang WZ
    J Neuroimmunol; 2007 Dec; 192(1-2):206-14. PubMed ID: 17997492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.
    Jacobs BC; O'Hanlon GM; Bullens RW; Veitch J; Plomp JJ; Willison HJ
    Brain; 2003 Oct; 126(Pt 10):2220-34. PubMed ID: 12876146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
    Alshekhlee A; Hussain Z; Sultan B; Katirji B
    J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
    Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement.
    Dada MA; Kaplan AA
    Ther Apher Dial; 2004 Oct; 8(5):409-12. PubMed ID: 15663537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
    França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of immunoglobulin in severe childhood Guillain-Barré syndrome.
    Ortiz-Corredor F; Peña-Preciado M
    Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion.
    Winger EE; Reed JL
    Am J Reprod Immunol; 2008 Jul; 60(1):8-16. PubMed ID: 18422811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.